N-[2-[2-(2-propan-2-yloxyethoxy)ethoxy]ethyl]propan-2-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[2-[2-(2-propan-2-yloxyethoxy)ethoxy]ethyl]propan-2-amine
• 化学式: C₁₂H₂₇NO₃
• 分子量: 233.35
• InChiKey: LMBJZJJIOIWWGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  39.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS INHIBITEUR DE TGFBETAR2-ANTICORPS ANTI-LRRC15 ET LEURS UTILISATIONS
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2021102332A1

  公开（公告）日：2021-05-27

  Conjugates comprising a TGFβR2 inhibitor and an anti-LRRC15 antibody, compositions comprising the conjugates, and use of the conjugates in the treatment of disease, such as fibrosis and cancer, are disclosed herein. Also disclosed herein are anti-LRRC15 antibodies, including humanized anti-LRRC15 antibodies.

  本文披露了包括TGFβR2抑制剂和抗LRRC15抗体在内的共轭物，包括这些共轭物的组合物，以及在治疗疾病（如纤维化和癌症）中使用这些共轭物的方法。本文还披露了抗LRRC15抗体，包括人源化的抗LRRC15抗体。
• BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME
  申请人：Coferon, Inc.

  公开号：US20140243322A1

  公开（公告）日：2014-08-28

  Described herein are compounds capable of modulating one or more biomolecules substantially simultaneously, e.g., modulating two or more binding domains (e.g., bromodomains) on a protein or on different proteins.

  本文描述了一些化合物，能够在实质上同时调节一个或多个生物分子，例如，在蛋白质上或不同蛋白质上调节两个或更多结合域（例如溴结构域）。
• MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE
  申请人：Yale University

  公开号：US20200121684A1

  公开（公告）日：2020-04-23

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Burton's Tyrosine Kinase (BTK). In particular, the present disclosure is directed to bifunctional compounds. One end of a bifunctional compound includes a Von Hippel-Lindau, Cereblon, Inhibitors of Apotosis Proteins, or Mouse Double-Minute Homolog 2 ligand that binds to the respective E3 ubiquitin ligase. The other end of a bifunctional compound includes a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein can be treated or prevented with compounds and compositions of the present disclosure.
• CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF
  申请人：SILVERBACK THERAPEUTICS, INC.

  公开号：US20220169660A1

  公开（公告）日：2022-06-02

  Cyclic amino-pyrazinecarboxamide compounds, salts, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed compounds are useful, among other things, in the treating of disease, for example cancer and/or fibrotic diseases, and modulating TGFβR2.